Literature DB >> 801578

Double blind comparison of fentanyl and sulfentanil in anesthesia.

J Van De Walle, P Lauwers, H Adriaensen.   

Abstract

In a double-blind experiment fentanyl and sulfentanil were compared using three different anesthesia schedules. Only interventions of long duration were selected. In all three systems induction was carried out with 0.5 mg fentanyl or 0.05 mg sulfentanil, followed by etomidate and a muscle relaxant. Anesthesia was maintained with nitrous oxide and with repeated standard injection of the narcotic. In a first group reinjections always consisted of 0.1 mg of fentanyl or 0.01 mg of sulfentanil. In a second series reinjections were done with 0.5 mg of fentanyl or 0.05 mg of sulfentanil. In the third group the same reinjection schedule as in the first group was followed, but immediately after induction an injection of 1.25 mg of droperidol was administered. Both substances were compared as to their analgesic potency and their potential influences on hemodynamics. Special attention was also paid to postoperative ventilation and vigilance.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 801578

Source DB:  PubMed          Journal:  Acta Anaesthesiol Belg        ISSN: 0001-5164


  3 in total

Review 1.  Sufentanil. A review of its pharmacological properties and therapeutic use.

Authors:  J P Monk; R Beresford; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

2.  Low-dose sufentanil and lidocaine supplementation of general anaesthesia.

Authors:  D C Cheng; F Chung; K R Chapman; J Romanelli
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

3.  Effect of additional equipotent fentanyl or sufentanil administration on recovery profiles during propofol-remifentanil-based anaesthesia in patients undergoing gynaecologic laparoscopic surgery: a randomized clinical trial.

Authors:  Chunyuan Zhang; Ding Huang; Wei Zeng; Jian Ma; Ping Li; Qichang Jian; Jiamin Huang; Huanlong Xie
Journal:  BMC Anesthesiol       Date:  2022-04-29       Impact factor: 2.376

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.